BioPharmSignal logoBioPharmSignal

Biotech News

Greenwich LifeSciences Presents FLAMINGO-01 Phase III Trial Open Label Data Published at ASCO Meeting 2026

Greenwich LifeSciences (GLSI)Greenwich LifeSciencesClinical readout

GLSI (GLSI) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is glsi.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Related news

GLSIGreenwich LifeSciences2026-07-20 10:00 EST

Greenwich LifeSciences Provides Clinical Updates on FLAMINGO-01

GLSIGreenwich LifeSciences2026-07-22 10:00 EST

Greenwich LifeSciences Announces Approval to Expand FLAMINGO-01 into the United Kingdom

IMTXImmatics2026-05-30 12:00 EST

Immatics Presents Clinical Activity of IMA203CD8 PRAME Cell Therapy in Hard-to-Treat Gynecologic Cancers at 2026 ASCO Annual Meeting

IMTXImmatics2026-05-31 13:00 EST

Immatics Presents Data on IMA401 MAGEA4/8 Bispecific at 2026 ASCO Annual Meeting with Simultaneous Publication in Nature Medicine Supporting Development of IMA401/IMA402 Combination in Lung Cancer

KYMRKymera2026-06-12 11:00 EST

Kymera Therapeutics Presents Phase 1 Data in Healthy Japanese Adults for KT-621, a First-in-Class Oral STAT6 Degrader, at the Japanese Dermatological Association Annual Meeting

COGTCogent Biosciences2026-05-30 12:00 EST

Cogent Biosciences Announces Detailed Clinical Data from PEAK Phase 3 Trial with Bezuclastinib in Combination with Sunitinib in Gastrointestinal Stromal Tumors (GIST) at 2026 American Society of Clinical Oncology (ASCO) Annual Meeting

REPLReplimune Group2026-05-30 12:00 EST

Replimune Presents 3-Year Landmark Overall Survival Analysis from IGNYTE Clinical Trial During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting

RVMDRevolution Medicines2026-05-31 12:06 EST

Revolution Medicines Announces ASCO Plenary Presentation Highlighting Unprecedented Results from Pivotal Phase 3 RASolute 302 Clinical Trial of Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer

GSKGSK plc2026-07-28 12:00 EST

GSK delivers strong Q2 core results performance and continued momentum. Plans announced to accelerate R&D and late-stage pipeline portfolio. Expect 20+ phase III trial starts in 2026

GSKGSK plc2026-07-28 11:00 EST

GSK’s licensor Hansoh Pharma announces positive results from a second phase III trial for Ris-Rez in China

View all latest news

Greenwich LifeSciences

Greenwich LifeSciences is an immunotherapy company focused on cancer vaccines and breast-cancer treatment. Its story is built around a narrow but potentially differentiated oncology program.

Recent company news

GLSIGreenwich LifeSciences2026-07-22 10:00 EST

Greenwich LifeSciences Announces Approval to Expand FLAMINGO-01 into the United Kingdom

GLSIGreenwich LifeSciences2026-07-20 10:00 EST

Greenwich LifeSciences Provides Clinical Updates on FLAMINGO-01

GLSIGreenwich LifeSciences2026-07-16 11:30 EST

Greenwich LifeSciences Announces European Approval for Combining Both HLA Populations in FLAMINGO-01

GLSIGreenwich LifeSciences2026-07-09 10:00 EST

Greenwich LifeSciences Announces European Approval for Use of Commercially Manufactured GP2 in FLAMINGO-01

GLSIGreenwich LifeSciences2026-06-01 12:15 EST

Greenwich LifeSciences Presents FLAMINGO-01 Phase III Trial Open Label Data Published at ASCO Meeting 2026

Stock data

Close
14.24 USD
Market cap
356.53M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States